Comparison of the Effects of Vaginal Hyoscine Butylbromide and Misoprostol on Cervical Preparation for Gynecological Intrauterine Interventions: A Double-Blind Clinical Trial

Effective cervical preparation is crucial for procedures requiring transcervical uterine access. Insufficient dilation can complicate these interventions. While chemical agents are commonly used, the optimal method remains under investigation. This study aimed to compare the effectiveness and safety of vaginal hyoscine butylbromide versus vaginal misoprostol for cervical preparation prior to gynecological intrauterine surgery. This double-blind, randomized controlled trial included 71 women scheduled for gynecological intrauterine interventions requiring cervical preparation. Participants were randomly assigned to receive either vaginal hyoscine butylbromide (n=36, 40 mg total dose) or vaginal misoprostol (n=35, 200 µg) 2-4 hours before the procedure. The primary outcome was the diameter of the first Hegar dilator that could be inserted through the internal os without resistance. Secondary outcomes included cervicovaginal-uterine complications and drug-related side effects. The mean diameter of the first dilator passed without force was (4.91 ± 1.10) mm in the hyoscine group and (5.54 ± 1.50) mm in the misoprostol group; this difference was not statistically significant (P = 0.081). Notably, the incidence of uterine pain and cramping was significantly lower in the hyoscine group (0% vs. 34.3%, P < 0.001), representing a key clinical advantage. No significant differences were observed in other complications or side effects between the groups. No cases of uterine or cervical rupture occurred. Vaginal hyoscine butylbromide demonstrated comparable cervical dilation to misoprostol but resulted in significantly less uterine pain and cramping, which constitutes a meaningful clinical advantage. The complete elimination of uterine cramping in the hyoscine group highlights its distinct benefit as a cervical priming agent. Hyoscine appears to be a safe and more comfortable option for cervical preparation in premenopausal women undergoing gynecological procedures.

Authors

Institutions

Publication Details

Journal
AJOG Global Reports
Published
2026-03-01
DOI
https://doi.org/10.1016/j.xagr.2026.100626
Primary Topic
Preterm Birth and Chorioamnionitis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of the Effects of Vaginal Hyoscine Butylbromide and Misoprostol on Cervical Preparation for Gynecological Intrauterine Interventions: A Double-Blind Clinical Trial

Majid Mirmohammadkhani, Sadra Sarandili, Safa Mousavi, Mahshid Khakzad et al.
AJOG Global Reports
Preterm Birth and Chorioamnionitis
article

Comparison of the Effects of Vaginal Hyoscine Butylbromide and Misoprostol on Cervical Preparation for Gynecological Intrauterine Interventions: A Double-Blind Clinical Trial

Majid Mirmohammadkhani, Sadra Sarandili, Safa Mousavi, Mahshid Khakzad, Shahrzad Aghaamoo
article en

Abstract

Effective cervical preparation is crucial for procedures requiring transcervical uterine access. Insufficient dilation can complicate these interventions. While chemical agents are commonly used, the optimal method remains under investigation. This study aimed to compare the effectiveness and safety of vaginal hyoscine butylbromide versus vaginal misoprostol for cervical preparation prior to gynecological intrauterine surgery. This double-blind, randomized controlled trial included 71 women scheduled for gynecological intrauterine interventions requiring cervical preparation. Participants were randomly assigned to receive either vaginal hyoscine butylbromide (n=36, 40 mg total dose) or vaginal misoprostol (n=35, 200 µg) 2-4 hours before the procedure. The primary outcome was the diameter of the first Hegar dilator that could be inserted through the internal os without resistance. Secondary outcomes included cervicovaginal-uterine complications and drug-related side effects. The mean diameter of the first dilator passed without force was (4.91 ± 1.10) mm in the hyoscine group and (5.54 ± 1.50) mm in the misoprostol group; this difference was not statistically significant (P = 0.081). Notably, the incidence of uterine pain and cramping was significantly lower in the hyoscine group (0% vs. 34.3%, P < 0.001), representing a key clinical advantage. No significant differences were observed in other complications or side effects between the groups. No cases of uterine or cervical rupture occurred. Vaginal hyoscine butylbromide demonstrated comparable cervical dilation to misoprostol but resulted in significantly less uterine pain and cramping, which constitutes a meaningful clinical advantage. The complete elimination of uterine cramping in the hyoscine group highlights its distinct benefit as a cervical priming agent. Hyoscine appears to be a safe and more comfortable option for cervical preparation in premenopausal women undergoing gynecological procedures.

AJOG Global Reports
Tabriz University of Medical Sciences (IR), Curtin University (AU), Government of Western Australia Department of Health (AU), Semnan University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 10%
Preterm Birth and Chorioamnionitis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.